The effect of switching to aripiprazole on indices of cardiovascular health in overweight and obese patients with schizophrenia

Trial Profile

The effect of switching to aripiprazole on indices of cardiovascular health in overweight and obese patients with schizophrenia

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2008

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2008 Status changed from in progress to completed.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top